

VIA FACSIMILE TRANSMISSION  
Date of Deposit: January 16, 2002

Attorney Docket No. 22058-521

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Keith et al.  
SERIAL NUMBER: 09/521,696 EXAMINER: J. Seharaseyon  
FILING DATE: March 9, 2000 ART UNIT: 1647  
FOR: Use of Interleukin-11 To Prevent Immune-Mediated Cytotoxicity

Assistant Commissioner for Patents  
Washington, D.C. 20231

## SUPPLEMENTAL RESPONSE

Further to the Amendment submitted November 26, 2001 for the above-referenced application, applicants submit herewith a clean copy of the claim amendments and new claims added.

B1  
sub C17  
1. (Amended) A method of preventing complement-mediated cytotoxicity in a mammal which comprises  
C  
identifying a mammal at risk of developing complement-mediated cytotoxicity; and  
administering to said mammal, prior to tissue transplantation, a therapeutically effective amount of interleukin-11, wherein said amount of IL-11 prevents complement-mediated cytotoxicity in said mammal.

B2  
sub C27  
3. (Amended) A method of ameliorating complement-mediated cytotoxicity in a mammal which comprises  
C  
identifying a mammal at risk of developing complement-mediated cytotoxicity; and